Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) FCF Margin (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed FCF Margin for 16 consecutive years, with 30.99% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, FCF Margin fell 2756.0% year-over-year to 30.99%, compared with a TTM value of 3.03% through Sep 2025, up 1606.0%, and an annual FY2024 reading of 11.89%, down 174.0% over the prior year.
  • FCF Margin was 30.99% for Q3 2025 at China Pharma Holdings, down from 28.07% in the prior quarter.
  • Across five years, FCF Margin topped out at 52.11% in Q3 2023 and bottomed at 72.04% in Q1 2023.
  • Average FCF Margin over 5 years is 10.17%, with a median of 7.86% recorded in 2024.
  • The sharpest move saw FCF Margin plummeted -5955bps in 2022, then skyrocketed 5381bps in 2023.
  • Year by year, FCF Margin stood at 7.1% in 2021, then surged by 395bps to 20.95% in 2022, then plummeted by -106bps to 1.25% in 2023, then surged by 1408bps to 16.34% in 2024, then crashed by -290bps to 30.99% in 2025.
  • Business Quant data shows FCF Margin for CPHI at 30.99% in Q3 2025, 28.07% in Q2 2025, and 10.22% in Q1 2025.